{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:31:00Z","timestamp":1789381860288,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T00:00:00Z","timestamp":1674345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.01.032","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:24:26Z","timestamp":1674447866000},"page":"1925-1933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-1530","authenticated-orcid":false,"given":"Saad I.","family":"Mallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3682-3677","authenticated-orcid":false,"given":"Abdulla","family":"Alawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaleela","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-8240","authenticated-orcid":false,"given":"Pearl","family":"Wasif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-2703","authenticated-orcid":false,"given":"Basma","family":"Alsaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9757-8914","authenticated-orcid":false,"given":"Ejlal","family":"Alalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afaf Merza","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-3917","authenticated-orcid":false,"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool","family":"Alalawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donia","family":"Qayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Ali","family":"Almahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-2675","authenticated-orcid":false,"given":"Ali","family":"Mubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalaa","family":"Mubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Humaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-3730","authenticated-orcid":false,"given":"Nitya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-7257","authenticated-orcid":false,"given":"Stephen","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-0429","authenticated-orcid":false,"given":"Manaf","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.032_b0005","unstructured":"\u201cWHO Coronavirus (COVID-19) Dashboard\u201d.Covid19.Who.Int, 2021, https:\/\/covid19.who.int\/. Accessed 24 Dec 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.032_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-021-00438-7","article-title":"COVID-19: breaking down a global health crisis","volume":"20","author":"Mallah","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.vaccine.2023.01.032_b0015","article-title":"Lives and Costs Saved by Expanding and Expediting COVID-19 Vaccination","author":"Bartsch","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.032_b0020","doi-asserted-by":"crossref","unstructured":"Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis 2021; 21(1): 39\u201351. doi:10.1016\/ S1473-3099(20)30831-8.","DOI":"10.1016\/S1473-3099(20)30831-8"},{"key":"10.1016\/j.vaccine.2023.01.032_b0025","unstructured":"https:\/\/cdn.who.int\/media\/docs\/defaultsource\/immunization\/sage\/2021\/april\/2_sage29apr2021_critical-evidence_sinopharm.pdf."},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.032_b0030","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"6561","key":"10.1016\/j.vaccine.2023.01.032_b0035","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.032_b0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"Cox","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.01.032_b0045","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants","volume":"325","author":"Moore","year":"2021","journal-title":"JAMA"},{"issue":"1284\u201394","key":"10.1016\/j.vaccine.2023.01.032_b0050","first-page":"e9","article-title":"The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"issue":"2362\u201371","key":"10.1016\/j.vaccine.2023.01.032_b0055","first-page":"e9","article-title":"SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.01.032_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00413-6","article-title":"Severe breakthrough COVID-19 infections in Scotland\u2014implications for immunisation programmes","author":"Leshem","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"158","key":"10.1016\/j.vaccine.2023.01.032_b0065","article-title":"Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain","volume":"1","author":"Jahromi","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2023.01.032_b0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-5699(00)01612-1","article-title":"The prime-boost strategy: exciting prospects for improved vaccination","volume":"21","author":"Ramshaw","year":"2000","journal-title":"Immunol Today"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.032_b0075","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/14760584.2021.1971522","article-title":"To mix or not to mix? A rapid systematic review of heterologous prime\u2013boost covid-19 vaccination","volume":"20","author":"Chiu","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.032_b0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jama.2021.10823","article-title":"Sharing technology and vaccine doses to address global vaccine inequity and end the COVID-19 pandemic","volume":"326","author":"Kavanagh","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.01.032_b0085","unstructured":"Department of Health. Research governance framework for health and social care. Health Do. 2005 Apr."},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.032_b0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.032_b0095","unstructured":"cPass SARS-CoV-2 Neutralization Antibody Detection Kit Instructions for use. Version 7. Fda.gov (2022). Available at: https:\/\/www.fda.gov\/media\/143583\/download"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.032_b0100","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s11357-021-00471-6","article-title":"Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans","volume":"43","author":"V\u00e1lyi-Nagy","year":"2021","journal-title":"GeroScience"},{"issue":"7830","key":"10.1016\/j.vaccine.2023.01.032_b0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.032_b0110","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/vaccines9111223","article-title":"Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers","volume":"9","author":"Alqassieh","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.01.032_b0115","first-page":"1","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"17","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.032_b0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.032_b0125","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","author":"Earle","year":"2021","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.032_b0135","doi-asserted-by":"crossref","first-page":"e02107","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate","volume":"58","author":"Addetia","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"16","key":"10.1016\/j.vaccine.2023.01.032_b0140","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0145","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","author":"Clemens","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.032_b0150","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"issue":"10289","key":"10.1016\/j.vaccine.2023.01.032_b0155","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.032_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a Single-Blind, randomised, non-inferiority trial","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.vaccine.2023.01.032_b0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.032_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants","volume":"75","author":"Gro\u00df","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.01.032_b0175","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet","author":"Hillus","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0180","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study","volume":"18","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Regional Health-Europe"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.032_b0185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJMc2110716","article-title":"Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination","volume":"385","author":"Normark","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0190","doi-asserted-by":"crossref","unstructured":"Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, Pan H, Wang X, Song Z, Wan J, Cui L. Heterologous prime-boost immunization with CoronaVac and Convidecia. medRxiv. 2021 Jan 1.","DOI":"10.1101\/2021.09.03.21263062"},{"key":"10.1016\/j.vaccine.2023.01.032_b0195","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab166","article-title":"Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin","author":"Kant","year":"2021","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0200","doi-asserted-by":"crossref","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant. New Engl J Med 2022 Apr 21; 386(16): 1532\u201346.","DOI":"10.1056\/NEJMoa2119451"},{"key":"10.1016\/j.vaccine.2023.01.032_b0205","doi-asserted-by":"crossref","unstructured":"Pulliam JR, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021 Jan 1.","DOI":"10.1101\/2021.11.11.21266068"},{"key":"10.1016\/j.vaccine.2023.01.032_b0210","doi-asserted-by":"crossref","unstructured":"Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 2021 May; 593(7857): 130\u20135.","DOI":"10.1038\/s41586-021-03398-2"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.032_b0215","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.01.032_b0220","article-title":"Protection against Covid-19 by BNT162b2 booster across age groups","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0225","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2115624","article-title":"BNT162b2 Vaccine Booster and Mortality Due to Covid-19","author":"Arbel","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.032_b0230","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.0470","article-title":"Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.01.032_b0235","unstructured":"Thompson MG. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19\u2013Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance\u2014VISION Network, 10 States, August 2021\u2013January 2022. MMWR. Morbidity and Mortality Weekly Report 2022; 71."},{"key":"10.1016\/j.vaccine.2023.01.032_b0240","article-title":"COVID-19 Vaccine Makers Plan for Annual Boosters, but It\u2019s Not Clear They\u2019ll Be Needed","volume":"24","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.01.032_b0245","article-title":"Booster doses for inactivated COVID-19 vaccines: if, when, and for whom","author":"Croda","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:51Z","timestamp":1759404291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23000531"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}